Mirati Therapeutics, Inc.
NASDAQ:MRTX
Overview | Financials
Company Name | Mirati Therapeutics, Inc. |
Symbol | MRTX |
Currency | USD |
Price | 58.7 |
Market Cap | 4,117,669,755 |
Dividend Yield | 0% |
52-week-range | 27.3 - 64.41 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Charles M. Baum M.D., Ph.D. |
Website | https://www.mirati.com |
An error occurred while fetching data.
About Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD